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S_umary Cell cultures have been produced from five Wilms' tumours. All cultures had a finite lifespan and
a pattern of antigen expression which indicated that the cells were derived from the differentiated components
of the tumours. No cells showed any of the expected characteristics of the putative Wilms' tumour stem cell.
Nevertheless, in both cases where the original tumours showed a loss of heterozygosity at chromosome lIp
alleles, the cultured cells also demonstrated a loss of heterozygosity. Thus these cell cultures definitely
originated from Wilms' tumour tissue. The results demonstrate that cell cultures can be produced from the
differentiated tissues present in Wilms' tumours and that these non-immortal cells show no 'transformed'
phenotype. even though they possess the genetic changes present in the original tumour.
Wilms' tumour (nephroblastoma) is a malignant embryonal
kidney tumour, and is one of the commonest solid tumours
of childhood (Pochedly & Baum, 1984). There is now a great
deal of evidence which suggests that the development of this
tumour is associated with the loss of function of a recessive
gene on the short arm of chromosome 11 (1lpl3) (Brodeur,
1984; Housman et al., 1986; Porteous et al.. 1987; Shows et
al.. 1986; Solomon, 1984; Weissman et al.. 1987). This often
involves the loss or reduplication of part or all of the short
arm of chromosome 11, which can be detected by examining
the tumours for loss of heterozygosity at vanous poly-
morphic loci on chromosome 11 (Fearon et al., 1984; Glaser
et al.. 1986; Koufos et al., 1984; Orkin et al., 1984; Reeve et
al.. 1984). We have used this methodology to examine cell
lines which we have derived from several Wilms' tumours. in
order to assess whether they were truly tumour-derived.
Materials and methods
Cell culture
Cultures were initiated from fresh samples of Wilms'
tumours by mincing the tissue finely and then placing the
fragments in plastic flasks, in Dulbecco's modified Eagle's
medium. containing 15% fetal bovine serum, 10ngmnl-1
epidermal growth factor. 1 pgmr -1 hydrocortisone and
0.2Um 1 insulin. Mitomycin treated Swiss 3T3 cells (2-
4 x I0O cells per 25cm2 flask) were added as a feeder layer.
When outgrowths had established, they were passaged
routinely using trypsinlEDTA. at a 1:2 split ratio.
DNA analtsis
DNA was extractd from normal kidney tissue or lympho-
blastoid cell lines (N). Wilms' tumour tissue (W) or cultured
cells (C) using a guanidine isothiocyanate-density gradient
centrifugation method, as described by Maitland et al.
(1987). Ten microgram samples were digested with
appropriate restriction endonucleases, electrophoresed on I%
agarose gels and blotted on to nylon membranes ('Hybond-
N', Amersham International) using standard protocols
(Maniatis et al., 1982). Filters were prehybridised for 2h at
45-C in 2 x SSC (0.3M NaCl, 0.03M sodium citrate, pH7),
containing 33% formamide, 10xDenhardt's solution (0.2%
bovine serum albumin, 0.2% ficoll, 0.2% polyvinyl
pyrollidone), 10% dextran sulphate, 0.5% sodium dodecyl
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sulphate (SDS), 2mM EDTA and 100pgml- denatured
salmon sperm DNA (except when using miisatellite probes,
where carrier DNA was omitted). and then hybnrdised
overnight in the same solution containing a 32P-DNA probe
labelled to high specific activity (about 109c.p.m. per pg)
using the random-primed labelling method (Feinberg &
Vogelstein, 1983; Amersham 'multiprime' kit). Filters were
washed once in 2 x SSC at room temperature for 30mmn
then in 2xSSC, 0.5% SDS for 2h at 65-C and finally in
0.1 x SSC for 30mn at room temperature, and then exposed
to Hyperfilm-MP film (Amersham- at -70-C with
intensifying screens.
The Ilp probes used in this study were as follows:
CAT:pSP65 (Boyd et al., 1986), CALCA:phTB3 (Hoppener
et al.. 1984). HBG:pHd3.2 (Old et al., 1986), HBB:pPst,B
(Old et al.. 1982), INS:pHINS310 (Bell et al., 1981) and
HRASI :pEJ6.6 (Reeve et al., 1984).
The multilocus minisatellite probe 6.3 was used for DNA
fingerprinting (Jeffreys et al., 1985).
Immunofluorescence
Cultured cells were fixed in methanol acetone (1: 1. v Xv) and
then stained using indirect immunofluorescence (visualised
by FITC-labelled anti-mouse immunoglobulins; Dako).
The monoclonal antibodies used were to: vimentin
(Osborn et al., 1984; Amersham International), keratin (a
pan-epithelial anti-keratin monoclonal antibody; Leigh et al.
(1985); Dako), desmin (Debus et al. (1983), Amersham). a
neuroectodermal marker (UJ13A, Allan et al. (1983), kindly
supplied by Mr S. Bourne, Frenchay Hospital, Bristol) and
class I HLA (W632, Barnstable et al. (1978). Serotec).
Results
Of a total of 14 Wilms' tumour samples, cultures have been
derived from 11, and of these five have been studied in
detail. The properties of these cells and the tumours from
which they were derived are summarised in Tables I and II.
The morphology of the cells varied from fibroblastic
(Figure la) to a more epithelial shape (Figure lb). Two of
the cell lines contained only vimentin intermediate filaments
(Figure lc and Table II), whereas two others expressed
keratins as well as vimentin (Figure Id and Table II) and
one cell line expressed desmin in addition to vimentin
(Figure le and Table II). All the cells tested expressed class I
HLA, as shown by staining with the monoclonal antibody
W632 (Figure If and Table II), whereas none of the cells
tested stained positively for the 'neuroectodermal' marker
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Table I Wilms' tumours used to derive cell lines
Loss of lip
Patient code Twnour type Tumour histology heterozvgositv
WT1 Sporadic Tnrphasic, muscle present
WlT 1 Sporadic Triphasic, prominent epithelial +
differentiation
WT4 Sporadic Blastema and stroma
WT5 Sporadic Prominent blastema with focal rosetes +
and epithelial differentiation
W7T7 Wilms'-aniridia Triphasic with prominent stroma,
including muscle
Table H Properties of cell lines derived from Wilms' tumours
Maximum Imununofluorescence
passage Class 1
Patient code Cell morphology nmnber Vimentin Keratin Desmin UJ13A HLA
WTl Epithelial 7 + + - ND ND
WTll Epithelial 8 + + - - +
WT4 Fibroblastic 14 + - - ND ND
WA5 Fibroblastic 6 + - - - +
WT7 Fibroblastic 10 + - + - +
ND=not done.
Table m Chromosome lIp alleles in Wilms' tumours and cultured cells
INS
CAT CALCA HBGJ HBG2 HBB HBB Jlp.15-5
llpl3 JJpl5.4 JlplS55 llplS55 J1pJ55 1JpJ5.5 PvuII or
TaqI TaqI HindIII HindIII SinI BanHI Hinfi
- 1,2 1,2
- 1,2 1,2
ND
ND
ND
1,2
- - 1,2
1,2
2,2
ND ND ND
ND ND
1,2
1,1-
ND
- 1,2
- 1,2
ND 1,2
HRASJ HRASJ HRASJ
llpl5.5 lpl5.5 lIp15.5
BanHI MspI TaqI
1,2 1,2
1,2 1,2
- ND
_ ND
- ND
1.2
2,2
2.2
1.2
2,2
2.2
1.2
1.2
ND 1,2
1,2
1,2
1,2
2
2
1,2
1,2
1,2
2
2
1,2 1,2
2,2 2,2
ND 2,2
1,2
1.2
1,2
1,2
1,2
1,2
1, larger allele; 2, smaller allele; -, non-informative, i.e. normal tissue was homozygous; ND, not done or unreadable (alleles too
close together); N, normal tissue; T, Wilms' tumour tissue; C, Wilns' tumour cultures.
recognised by the monoclonal antibody UJI3A (data not
shown; Table HI). In all cases, the cells had a finite lifespan;
surviving only six to 14 passages in culture (Table II). They
all grew as monolayer cultures and showed no morpho-
logical evidence of a transformed phenotype.
All of the cell lines were derived from patients who were
heterozygous for various polymorphic lIp loci, detected
using probes to catalase (CAT), calcitonin (CALCA), beta
(HBB) and gamma-globin (HBGI and HBG2), insulin (INS)
and c-Ha-ras 1 (HRASI) and appropriate restriction endo-
nuclease digestions (Table III). Three patients showed no
loss of heterozygosity at any of these loci in their tumour
DNA when compared to their normal DNA (WTl, 4 and 7,
Table III). Since these tumours could not be distinguished
from the normal tissue by allele analysis, the alleles present
in the cultured cells were only investigated in one
representative case (WT7) and found to be identical at all six
enzyme/probe combinations examined (Table III).
Two tumours (WT5 and WTl1) showed loss of llp alleles
(Figure 2a and Table III); in the case of WT5, the tumour
showed a loss of heterozygosity at all informative llp loci,
whereas WTll showed loss of llpl5 but not llpl3 allelles
(Table III). Densitometric analysis of the autoradiographs
demonstrated that WT5 became homozygous for the
retained allelles, but that WTl became hemizygous (data
not shown).
At all loci examined in the cultured cells from WT5 and
WTI1, there was an identical pattern of loss of hetero-
zygosity as that found in the original tumour tissue (Figure
2a and Table III). This was shown for four informative
probe/enzyme combinations for WT5 and two combinations
for WTl1. In addition, WTll tumour cells retained hetero-
zygosity at llpl3, as found in the tumour tissue (Table III,
three enzyme/probe combinations).
The patient onrgin of these cell lines was confirmed by
'DNA fingerprinting' (Figure 2b), using a multilocus probe
to hypervariable minisatellite sequences (Jeffreys et al., 1985).
Thus these two cell lines (WT5 and 11) were genotypically
identical, at Ilp loci, to the tumours from which they
originated, and were therefore definitely derived from Wilms'
tumour tissue.
Wilms' tumour is thought to develop from the metanephric
blastema, an embryonic cell type, which is induced by the
developing ureteric bud to differentiate into both the epithelial
CAT
llpl3
SinI
CAT
llp13
KpnI
CAT
llp13
HaeIII
Marker
location
enzyme
WT1 N
T
WTlI N
T
C
W1T4 N
T
WT5 N
T
C
WU7 N
T
C
ND
ND
ND
1,2
1,2
1,2
1.2
1,2
1,2
1,2
1,2
1,2 1,2
1,1
ND
1,2
1,2
1,2
ND
1,2
1,2
ND
- 1,2
- 1,2
1,2
1,1
ND 1,1
1,2
1,2
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Fugwe I Morphology and antigen expression of cells cultured from Wihns' tumours? (a) and (b) phase contrast micrographs of
cells from WT7 and WTl I respectively. (c) to (f) immunofluorescence micrographs: (c) WT5 cells stained with anti-vimentin, (d)
WTII cells stained with anti-keratin, (e) WT7 cells stained with anti-desmin and (f) WT1 cells stained with anti-dass I HLA
(W632). Bar =20gm.
and stromal components of the mature kidney (Machin,
1984; Mierau & Beckwith, 1987; Ekblom, 1981). Wilms'
tumours classically contain three components (normally
referred to as a triphasic histology): (1) undifferentiated
blastema, (2) epithelial elements and (3) stroma (of which
striated muscle often forms a part); the latter two being
derived from the former (by analogy with normal kidney
development). Thus it is likely that the blastema represents
the malignant stem cell compartment of the tumour, and the
stromal and epitheial elements are differentiated derivatives
of the blastema.
Immunohistochemical studies using antibodies to
intermediate filament proteins have defined some of the in
vivo characteristics of the three components of Wilms'
tumour. (1) the blastema cells always contain vimentin and
may express keratins weakly in some areas, (2) the epithelial
cells contain only keratins and (3) the stromal cells contain
vimentin, and also desmin where striated muscle is present
(Altmannsberger et al., 1984; Denk et al., 1985; Kahn et al.,
1983; Yeger et al., 1985; Berry et al., unpublished results).
Additionally, it has been shown that the blastema cells do
not express class I HLA, whereas the differentiated cells do
(Borthwick et al., 1988; Shaw et al., 1988). In contrast, the
antibody UJ13A mainly stains the blastema in Wilms'
tumours (Berry et al., unpublished results).
Assuming that the various cell types maintain these
characteristics in culture, it seems likely that the cell lines
described in this paper are derived from the epithelial (in the
case of WTI and 11) and stromal (in the case ofWT4, 5 and 7)
elements of their respective tumours, and none show the
expected characteristics of blastema cells. One of the
strongest pieces of evidence in favour of this conclusion is
the finding that none of the cell lines tested stained positively
with the monoclonal antibody UJ13A (Table II). UJ13A
detects a fetal antigen originally described as a neuro-
ectodermal marker, but which is also expressed by blastema
cells and a few epithelial tubules in both fetal kidney and
Wilms' tumour (Allan et al., 1983; Berry et al., unpublished
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Figure 2 Loss of heterozvgosity at chroi
cells cultured from Wilms tumours.
patterns shown were obtained using a
Methods) on Ram-HI digests for patient
digests for patient WT 11. Allelic bands are
III. Allele I was lost in the tumour and
cases. (b) DNA 'fingerprints' were produa
Hinf-I digests with the multilocus minis
Methods). The positions of molecular weil
on the right of each set of tracks. Only ti
containing the polymorphic bands are sh4
tissue: W. Wilms tumour tissue: C. Wiln
results). Recent results have shown tha
the neural cell adhesion molecule (N-C
Kemshead. personal communication). a]
workers have confirmed that N-CAM i
tumours (Roth et al.. 1988) and in
nephrogenic mesenchyme (blastema)
(Klein et al., 1988). In addition. some o
5 and 7) have previously been shc
detectable levels of N-mYc RNA (!
although N-mc is expressed at high 1F
cells in Wilms' tumours in i'vo (Shaw
Our demonstration of the loss of
cultured cells derived from two tumc
Table III). provides unequivocal evid
cultures (WTS and WTl1) were ti
Although we have not been able to prs
obtained from tumours which showec
zygosity were tumour-derived, it is likelb
also derived from the differentiated p,
since all of them express class 1 H
positively with UJ13A. Preliminary cytc
of these latter cell lines (WT7) have shc
marker chromosome (data not shown)
cells were also tumour-derived.
LU (lays). A laCK O0 matenal (aue to tme tite htIespan ot
the cells) prevented a full study of the possible tumorigenic
potential of all the cell lines. However, we are not aware of
-2.3 any cases in which human cells with a finite culture lifespan
-2.0 have formed malignant tumours in nude mice.
The failure to establish permanent cell lines from Wilms'
tumours is consistent with many other earlier reports
(reviewed by Hard, 1984), and to the recent results reported
by Fraizer et al. (1987), who concluded that their non-
immortal cell lines were tumour-derived on the basis of
abnormal karyotypes. Our results and those of Fraizer et al.
(1987) clearly show that the derivation of cells resembling
-0.56 normal kidney cells from Wilms' tumours does not
necessarily represent a contamination with normal kidnev. as
proposed by others (Hard, 1984), but probably represents
WT1I the growth of cells from the non-malignant, differentiated
N W C kb parts of the tumours. 'C-a' Very few permanent cell lines have been established from
'(" a_ __ I _1 A'% L. __.s .s_' wilms tumours (Hard, 1964). tne most recent Deing a
desmin-positive non-tumongenic cell line, derived from a
-231 Wilms'-aniridia patient possessing a deletion on the short
-94 arm of chromosome 11 (Kumar et al.. 1987). Interestingly.
one of our cell lines was denrved from a Wilms'-amnridia
- 6.6 patient with an Ilp deletion (WT7), and this line was
desmin-positive (Figure le and Table II), presumably
- 4.4 originating from the differentiated striated muscle
component often found in Wilms' tumours. However. our
cell line did not establish in culture to form an immortal cell
2.3 line.
The results described in this paper clearly demonstrated
2.0 that the epithelial and stromal components of Wilms'
tumour can be cultured to give non-immortal cell lines.
which are nevertheless genotypically identical to their
parental tumours. Paradoxically. the inability to culture the
mosome llp alleles in stem cell component of Wilms' tumours may indicate a
(a) The polymorpiic strong potential for developing non-cytotoxic methods for
HRASI probe (see treating these and similar embryonal tumours, since conven-
bWT5 and on MSP-I tional culture conditions clearly select against the malignant
cultureDNA in both cells in the tumours (even when using feeder layers and
ed by probing blots of added growth factors, as in this paper).
atellite probe 6.3 (see Preliminary studies in our laboratory have shown that
ght markers are shown cells with some of the antigenic properties expected of the
he regions of the blots Wilms' tumour blastema (UJ13A-positive) are found in early
own in (a). N. normal primary cultures. However, these cells do not proliferate and
is' tumour cultures. can no longer be detected after 7 days under standard
it UJ13A reacts with culture conditions. We suggest that there may be factors in
--AM) (K. Patel & J. serum which inhibit the proliferation and or induce the
nd reports from other differentiation of the blastema cells. since UJ13A-positive
s expressed in Wilms cells show a far longer survival in serum-free media
the undifferentiated (unpublished observations). Interestingly. Garvin et al. (1987)
in mouse embryos have recently described a serum-free culture system which
f our cell lines (WT4. allows the proliferation of putative blastema cells for six to 12 passages. Similarly. our preliminary attempts to culture
Shaw et al 1988) Wilms' tumours (two samples) in serum-free medium have
evels in the blastema only given an extended survival of 'blastema' cells. without
et at.. 1988). the formation of immortal cell lines. Clearlv a full under-
lip allelles in the standing of the biology of Wilms' tumour requires the
:murs (Figure 2a and development of suitable conditions for the routine culture of
lence that these cell the blastema stem cell.
ruly tumour-derived. Some of the cell lines descnrbed in this paper are ve that the cell lines undoubtdly derived from Wilms' tumours. since they are
1 no loss of hetero- genotypically identical to their parental tumours. These cells
that these cells were can be immortalised by SV40 and have selectable markers
arts ofthe tumoursw introduced into them (Poinrer et al.. 1988). Such cell lines
[LA and none stain may provide an important long-term source of matenral for )genAc studies on one the study of the genetic alterations which lead to the
gwn the presence of a development of Wilms' tumour. for example. by use in cell
indicating that the fusion expenments. lll%Al%,"Ll116 LLI"L L11%-W-WILMS' TUMOUR CULTURES 29
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